Wspólnotowy Serwis Informacyjny Badan i Rozwoju - CORDIS

Informacje o projektach programu „Horyzont 2020” , a teraz także streszczenia sprawozdań , są dostępne w serwisie CORDIS. Wszystkie projekty H2020 można pobrać z Portalu Otwartych Danych UE .

My refinements


Download results of this page


Filtruj wg:

Advanced search

Wyszukiwanie projektów i wyników

Results 1 - 4 of 4
Order by: Results/page:
1
Adeno-Associated Virus Vector-Mediated Liver Gene Therapy for Crigler-Najjar Syndrome
ID: 755225
Data rozpoczęcia: 2018-01-01, Data zakończenia: 2022-12-31
Crigler-Najjar syndrome (CN) is a rare recessive disorder caused by mutations in the uridine diphosphate glucuronosyltransferase 1A1(UGT1A1) gene. CN is a life-threatening disease with no cure which constitutes a severe burden for the patients, their families, and the society...
Programme: H2020-EU.3.1.3.
Record Number: 212689
Last updated on: 2018-01-23
A global alliance for Zika virus control and prevention
ID: 734548
Data rozpoczęcia: 2016-10-01, Data zakończenia: 2019-09-30
"ZIKAlliance is a multidisciplinary project with a global ""One Health"" approach, built: on a multi-centric network of clinical cohorts in the Caribbean, Central & South America; research sites in countries where the virus has been or is currently circulating (Africa, Asia...
Programme: H2020-EU.3.1.3.
Record Number: 207455
Last updated on: 2017-08-23
Clinical Proof of concept for a RNA-targeting Oligonucleotide for a Cystic fibrosis-F508del MEDication
ID: 633545
Data rozpoczęcia: 2015-05-01, Data zakończenia: 2017-12-31
Cystic fibrosis (CF) is a progressive life-shortening disease caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene leading to a dysfunctional CFTR protein. The disease affects over 70,000 patients worldwide and while many mutations are...
Programme: H2020-EU.3.1.3.
Record Number: 193242
Last updated on: 2017-08-22
Development of an innovative gene therapy platform to cure rare hereditary muscle disorders
ID: 667751
Data rozpoczęcia: 2016-01-01, Data zakończenia: 2019-12-31
The objective of MYOCURE is to develop an innovative gene therapy platform to cure rare hereditary muscle disorders, specifically focusing on myotubular myopathy (MTM) and glycogen storage disorder (GSD) type II. These are attractive diseases for gene therapy since they...
Programme: H2020-EU.3.1.3.
Record Number: 199738
Last updated on: 2016-11-29
List retrieved on: 2018-09-19
Śledź nas na: RSS Facebook Twitter YouTube Zarządzany przez Urząd Publikacji UE W górę